Among the mechanisms responsible for primary or acquired resistance to endocrine therapies is the loss of estrogen and/or progesterone receptor expression, which may render breast cancer cells independent of estrogen stimulation and, consequently, resistant to estrogen deprivation or pharmacological inhibition of estrogen receptors. The gene discussed is PGR; the disease is breast carcinoma.